Incretin-Based Therapies for Type 2 Diabetes
Mechanism-Based Strategies to Achieve Patient-Centered Care
Meeting Slides
Suggested Readings
Standards of Medical Care in Diabetes-2012.
American Diabetes Association. Diabetes Care. 2012;35:S11-S63.
Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action.
Campbell JE, Drucker DJ. Cell Metab. 2013;17:819-837.
AACE Comprehensive Diabetes Management Algorithm.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. 2013. Endocr Pract. 2013;19:327-336.
Novel Therapies for the Management of Type 2 Diabetes Mellitus: Part 2. Addressing the Incretin Defect in the Clinical Setting in 2013.
Grunberger G. J Diabetes. 2013;5:241-253.
Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes.
Holst JJ, Knop FK, Vilsboll T, Krarup T, Madsbad S. Diabetes Care. 2011;34 (suppl 2):S251-S257.
Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database.
Horton ES, Silberman C, Davis KL, Berria R. Diabetes Care. 2010;33:1759-1765.
Exenatide Once Weekly: Sustained Improvement in Glycemic Control and Cardiometabolic Measures Through 3 Years.
Macconell L, Pencek R, Li Y, Maggs D, Porter L. Diabetes Metab Syndr Obes. 2013;6:31-41.
Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes.
Scheen AJ. Postgrad Med. 2013;125:7-20.
The Role of Co-morbidity in the Selection of Antidiabetic Pharmacotherapy in Type-2 Diabetes.
Tschope D, Hanefeld M, Meier JJ, et al. Cardiovasc Diabetol. 2013;12:62.
Blood Pressure-Lowering Effects of GLP-1 Receptor Agonists Exenatide and Liraglutide: a Meta-Analysis of Clinical Trials.
Wang B, Zhong J, Lin H, et al. Diabetes Obes Metab. 2013;15:737-749.
Interactive PresentationScientific Insights Into Incretin Signaling and Type 2 Diabetes
Jack L. Leahy, MD
Relevant Resources
Patient-Centered Management of Hyperglycemia in Primary Care
Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens
Translating Research Into Practice
Translating Reseach Into Practice
Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes
Discussions and Debates Around GLP-1 Receptor Agonists
Evolving Roles of GLP-1 Receptor Agonists
Individualizing Evidence-Based Care
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Best Practices in Diagnosis and Management
New Strategies for Insulin Replacement Therapy
Consensus and Controversies Around Intensifying Noninsulin Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies
Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management
Evolving Roles of GLP-1 Receptor Agonists
Looking Beyond Hemoglobin A1c
What You Need to Know
Mechanistic Insights and Evolving Treatment Options
Implications for PCSK9 Inhibitors in Clinical Practice
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Multidimensional Outcomes With SGLT2 Inhibitors
New Avenues to Improve Patient Outcomes
Best Practices for Screening, Diagnosis, and Management
